Created by the team at GTS, the Ulthera system would become the world’s first, FDA cleared, combined imaging and therapy device. Ulthera is uniquely capable of safely penetrating and treating various layers of tissue, non-invasively. The device simultaneously allows physicians to see where they are working, in real time, beneath the skin. Ulthera remains the only non-invasive procedure FDA-cleared to lift skin on the neck, under the chin and on the eyebrow, and was most recently cleared FDA-cleared to improve the appearance of lines and wrinkles on the décolletage.

During the procedure, the outer epidermal layer of skin is completely spared while intense therapeutic ultrasound immediately activates the body’s natural healing effect, resulting in a gradual lifting and tightening of skin tissue in and around the face and neck area. Tissue is only thermally coagulated at the focal point, sparing the skin’s surface and all intervening tissue.


Ulthera was founded in 2004, to be GTS’s commercial partner in the Aesthetic market. Dr. Slayton, CEO of Guided Therapy Systems remained a board member of Ulthera until the company was acquired by Merz Pharma in 2014. Ulthera/Merz remains GTS’s exclusive licensee in the professional aesthetic market, selling Ulthera products around the world to dermatologists, plastic surgeons and other clinicians. 

For more information about Ulthera products, please visit:



The latest ITU platform from GTS, Actisound, effectively treats pain resulting from chronic soft tissue injuries. This ablative procedure is non-invasive and performed on tendons, ligaments, and other soft tissue deep within the body to stimulate connective tissue regeneration for optimum recovery time and return to mobility.

Similar to the Ulthera system, Intense therapeutic ultrasound is delivered to the desired target level deep below surface of the skin to induce small zones of thermal ablation. The procedure, as a result, activates and accelerates the body’s natural mechanism of healing, repairing damaged tissue and strengthening the surrounding tissue.

In chronic patients (average 15.7 months) Actisound is proven to reduce pain and inflammation within 48-72 hours and provide full recovery of soft tissue injuries within 12 weeks, all without breaking the skin. The ITU technology can initially be used to treat Plantar Fasciitis, Lateral Epicondylitis, and other soft tissue injuries.




The completely non-invasive treatment acts like an invisible scalpel and can be performed in the office setting. The procedure takes only about 10 minutes and works without the complications or recovery time associated with minimally invasive procedures or traditional surgeries requiring an incision.

Actisound is CE marked and is currently available in select European countries to licensed practitioners including: Orthopedic Surgeons, Foot and Ankle Surgeons, Podiatrists, Sports Medicine Physicians, Physical Medicine and Rehabilitation Physicians, Rheumatologists and Primary Care Physicians. Interested physicians can reach out for more information here. This product is not currently cleared for sale in the United States.

For more information about Actisound products, please visit:

Emerging Applications

Emerging Applications

In addition to lifting, tightening and wrinkle reduction, GTS is developing a number of professional and consumer applications for:

  • Acne treatment
  • Cellulite Conditions
  • Fat Reduction
  • Hair Removal or Growth
  • Hyperhidrosis
  • Mastopexy
  • Reduction in Appearance of Scars and Stretch Marks
  • Tattoo Removal

GTS has also recently introduced novel concepts in drug delivery associated with ITU, high-frequency and high intensity ultrasound. One method uses tiny micro-channels created in skin by micro-needles or lasers, painlessly penetrating through the top surface of the skin and transferring drugs efficiently via the application of ITU to the skin. Another method constitutes application of high intensity, very short pulses of ITU and delivering drugs through the skin barrier noninvasively.

Form more information on emerging applications, please contact us at